Trial
NCT03448692
A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Pfizer
Collaborators
—
Condition
Focal Segmental Glomerulosclerosis (FSGS)
Intervention
PF-06730512
Why stopped
The study was terminated due to lack of efficacy at both tested doses on 5th December 2022. The decision to terminate the study is not related to a safety concern.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-04-18